An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
Status:
Completed
Trial end date:
2017-09-21
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled,
dose-escalation study in subjects with relapsing Multiple Sclerosis (MS). The primary outcome
will be the safety and tolerability of a single dose of rHIgM22 in relapsing MS subjects.